Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da F. Moda

Microbiota intestinale e nasale nella malattia di Parkinson
Gut and nasal microbiota in Parkinson’s disease.
<p><span style="color:#221E1F; font-family:calibri,sans-serif; font-size:9.0pt">Parkinson&rsquo;s disease (PD) is a neurodegenerative condition characterized by a series of symptoms that anticipate overt disease. In particular, rapid eye movement (REM) sleep behavior disorders, intestinal problems and olfactory impairment are the most frequent prodromal signs of the disease. Compelling evidence suggests that, among other factors, the microbiota might play an important role in the onset and progression of PD. While several findings confirmed that there might be an important link between intestinal microbiota alterations and PD onset, little is known about the potential contribution of the nasal microbiota. Here, we will describe the latest findings on this topic by considering that more than 80% of patients with PD develop remarkable olfactory deficits in their prodromal disease stage. Therefore, the nasal microbiota might contribute to PD, eventually boosting the intestinal microbiota in promoting disease onset.</span></p>
Biochimica Clinica ; 46(3) 201-208
Rassegne - Reviews
 
Recenti sviluppi nella diagnosi differenziale tra malattia di Parkinson e parkinsonismi atipici
Recent advances in the differential diagnosis of Parkinson’s disease and atypical parkinosnisms
FA. Cazzaniga  |  AE. Elia  |  F. Moda  | 
<p>The presence of &alpha;-synuclein aggregates in the brain is the main hallmark of Parkinson&rsquo;s disease (PD) as well of other atypical parkinsonisms, including multiple system atrophy (MSA) and dementia with Lewy bodies (DLB). The in vivo diagnosis of these disorders is based on clinical criteria that are characterized by unsatisfactory sensitivity and specificity. Several cases thus might be misdiagnosed, especially in the early stages when clinical symptoms overlap. A definite diagnosis can be achieved only at post-mortemafter the identification of &alpha;-synuclein aggregates in the brain. According to the disease, these aggregates affect specific cells and brain areas and are characterized by typical biochemical and morphological features. As a consequence, they are considered disease-specific biomarkers that remain confined to the brain. However, thanks to the development of an ultrasensitive technique named Real-Time Quaking Induced Conversion (RT-QuIC), traces of these specific biomarkers, undetectable with the standard diagnostic techniques, were found in the cerebrospinal fluid (CSF) and olfactory mucosa (OM) of patients with PD, DLB and MSA. This technology is currently being exploited for the analysis of OM and other peripheral tissues such as urine and blood that might contain these biomarkers, likely encapsulated in brain-derived vesicles (e.g. microvesicles, exosomes). For this reason, RT-QuIC could be soon introduced in the field of PD, DLB and MSA diagnosis, finally leading to early diagnosis and patient stratification by a simple OM, blood or urine analysis.</p>
Biochimica Clinica ; 44(2) 119-128
Rassegne - Reviews